Objective: Seizures can be provoked by systemic diseases associated with metabolic derangements, but the association between liver disease and seizures remains unclear.
| INTRODUCTION
Chronic liver disease imposes a heavy public health burden, leading to approximately 2 million outpatient visits and 750 000 hospitalizations annually in the United States alone 1 and approximately 1 million deaths annually worldwide. 2 Neurological phenomena such as asterixis, encephalopathy, coma, and seizures are not infrequently observed in acute and chronic liver disease. Adams and Foley reported seizures in up to 30% of their observed cohort of patients with liver disease. 3 Many reports describe seizures in the setting of cerebral edema from acute liver failure, 4, 5 and convulsions have also been variably reported in chronic liver patients. 6 Finally, additional case reports exist of convulsive status epilepticus, epilepsia partialis continua, and electrographic seizures among patients with liver disease. [7] [8] [9] However, because it is unknown whether liver disease is an independent risk factor for seizures, we examined the association between cirrhotic liver disease and, separately, mild noncirrhotic chronic liver disease, and seizures.
| MATERIALS AND METHODS

| Study design
We performed a retrospective cohort study using inpatient and outpatient claims between 2008 and 2015 from a random 5% sample of Medicare beneficiaries. The US federal government's Centers for Medicare and Medicaid Services (CMS) provide health insurance to a large majority of US residents once they reach 65 years of age. CMS makes available to researchers data on claims submitted by providers and hospitals in the course of Medicare beneficiaries' clinical care. 10 Claims data from hospitals include Interna- 
| Patient population
Following standard methods in the analysis of Medicare data, we included only beneficiaries ≥65 years of age with continuous coverage in traditional fee-for-service Medicare (both Parts A and B) for at least 1 year (or until death, if applicable) and no enrollment in a Medicare Advantage plan. 11 We included beneficiaries only after 1 year of coverage eligibility to allow time for beneficiaries' files to accrue claims that reflect their baseline comorbidities.
Patients with a diagnosis of seizure before 1 year of coverage eligibility were excluded.
| Measurements
The primary exposure was cirrhosis, and the secondary exposure was mild, noncirrhotic liver disease. The primary outcome was seizure, and the secondary outcome was status epilepticus. We used validated algorithms to identify patients with liver disease and seizure. 12 13 To be classified as having cirrhosis, patients required at least 1 hospital discharge diagnosis or 2 outpatient diagnoses. We did not include patients with biliary cirrhosis in our analyses because of the diagnosis code's low specificity. 13 Administrative claims data have been used to identify patients with cirrhosis with good reliability in multiple additional settings. [13] [14] [15] We ascertained seizures using the following ICD-9-CM codes: 345.9, 345.3, 345.1, 345.8, 345.5, 345.4, 345.7, 345.0, 345.2, and 345.6. This code algorithm has previously been shown to have a positive predictive value of 84%-98% in adult patients. 12 We defined secondary outcome as status epilepticus (ICD-9-CM code 345.3). We identified mild liver disease using the following diagnosis codes: 070. • In our population-based study, we found an association between cirrhosis and status epilepticus
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In addition to general medical comorbidities, 16 we prespecified several seizure risk factors to include among our covariates: cerebrovascular disease, central nervous system tumors, traumatic brain injury, and central nervous system infections. In terms of cerebrovascular disease, prior diagnoses of ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhages were ascertained using a validated ICD-9-CM algorithm. 17 
| Statistical analysis
Patients' baseline characteristics were compared using the v 2 test and the t test, as appropriate. Crude rates were reported using descriptive statistics with exact 95% confidence intervals (CIs Table 2 ). The annual seizure incidence rate was 0.61% (95% CI = 0.60%-0.61%) in those without cirrhosis and 1.17% (95% CI = 1.03%-1.33%) in those with cirrhosis. Patients with cirrhosis had a higher risk of seizure in an unadjusted model (hazard ratio [HR] = 1.7, 95% CI = 1.5-2.0) and after adjustment for demographic characteristics (HR = 1.8, 95% CI = 1.6-2.0). However, after adjustment for demographic characteristics, general medical comorbidities, and the prespecified seizure risk factors of cerebrovascular disease, central nervous system tumors, traumatic brain injury, and central nervous system infections, there was no longer a significant association (HR = 1.1, 95% CI = 1.0-1.3, P = .06). There remained a significant association between cirrhosis and status epilepticus in models adjusting for demographics and comorbidities (HR = 1.9, 95% CI = 1.3-2.8; Figure 1 ).
| Risk of seizure in patients with mild liver disease
We identified 19 557 patients with mild liver disease. The annual incidence of seizure was the same among patients with mild liver disease 0.6% (95% CI = 0.5%-0.7%) versus the general population (0.6%, 95% CI = 0.6%-0.61%). We found no association between mild liver disease and an increased risk of seizures in an unadjusted model (HR = 0.9, 95% CI = 0.8-1.0, P = .13) or a model adjusted for demographics and comorbidities (HR = 0.7, 95% CI = 0.6-0.8). There was also no association between mild liver disease and status epilepticus in the adjusted model (HR = 1.1, 95% CI = 0.7-1.5; Figure 1 ).
| DISCUSSION
In a large, nationally representative sample of Medicare beneficiaries, we generally found no association between liver disease and seizures. Of the 4 associations that we tested, we found an association between liver disease and increased seizure risk only in the case of cirrhosis and status epilepticus.
Prior reports have described seizures and status epilepticus as manifestations of liver disease, more often in acute liver failure and less often chronic liver failure. [4] [5] [6] [7] [8] [9] The relationship between liver disease and seizure should be interpreted cautiously, as electroencephalographic (EEG) interpretation may change among electroencephalographers. Conversely, other literature suggests an increased c-aminobutyric acidergic tone in patients with acute and chronic liver failure as a result of increased pregnenolone, and the progesterone metabolites tetrahydroprogesterone (allopregnanolone) and tetrahydrodeoxycorticosterone, 18 which would argue against the hypothesis that liver disease might cause seizures. However, there is also an increase in proinflammatory cytokines in this population, which may lead to increased epileptogenesis. 19, 20 Amidst this uncertainty, our population-based study suggests that, on the whole, liver disease is not an independent risk factor for seizures. The one exception is the association that we found between cirrhosis and status epilepticus. This could represent a true link indicating that cirrhosis can increase the risk of seizures that are prolonged and severe. For example, liver cirrhosis may reduce the seizure threshold in individuals with other seizure risk factors and thus create a favorable milieu for status epilepticus. However, it may also be a spurious association due to detection bias from more frequent hospitalizations in patients with cirrhosis, or it may be a chance finding given the multiple hypotheses we tested, the generally negative association between cirrhosis and seizures, and the very small number of patients with status epilepticus. Additionally, the observed association may reflect misinterpretation of triphasic waves or other generalized periodic patterns as status epilepticus in the setting of severe encephalopathy. The association between cirrhosis and status epilepticus therefore requires further study before any definitive inferences can be made. Our study has multiple limitations. First, we used ICD-9-CM codes to identify patients with seizures and liver disease, which may have resulted in misclassification of our exposure and outcome. We think this is unlikely, because we used previously validated codes for liver disease and seizures, 12, 13 and we have previously found robust associations with other conditions in patients with cirrhosis and seizures. 21, 22 Second, we lacked data on the characteristics of EEG and neuroimaging findings, as well as data on medication use, so we cannot account for the confounding effects of antiepileptic or epileptogenic drugs that may have been used in our patient population. Third, our analysis was based on Medicare beneficiaries and may not be generalizable to younger populations.
In conclusion, our population-based study suggests that although metabolic derangements often cause seizures, and although liver disease is often associated with metabolic derangements and neurological deficits such as encephalopathy, there is generally no independent association between liver disease and seizures.
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